| Description | KRM-III is an orally active T cell antigen receptor (TCR) inhibitor with anti-inflammatory activity that potently inhibits TCR and myristate acetate/fosfomycin/ionomycin-induced NFAT nuclear factor activation and T cell proliferation, with an IC50 of approximately 5 μM. |
| Target activity | Proliferation (T-cells):~5 μM |
| molecular weight | 252.33 |
| Molecular formula | C15H12N2S |
| CAS | 79220-94-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 25.23 mg/mL (100 mM), Sonication is recommended. |
| References | 1. Jung EJ, et al. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model. J Pharmacol Exp Ther. 2009 Dec;331(3):1005-13. |